جست‌وجوی استاد و پژوهشگر

• Cancer Biology
• Genome Editing
• Molecular Biology
• +۳ مورد دیگر

Wen Xue is a Professor at UMass Chan Medical School, affiliated with the RNA Therapeutics Institute within the T.H. Chan School of Medicine. She holds multiple additional roles across departments such as the Program in Molecular Medicine, Cancer Biology, and Biochemistry and Molecular Biotechnology at the Morningside Graduate School of Biomedical Sciences. Her research focuses on developing genetic models for liver and lung cancer using CRISPR/Cas9 and RNAi tools. Key areas include CRISPR-mediated genome editing for cancer gene discovery, KRAS inhibition mechanisms, and miRNA networks in lung cancer. She has secured grants from NIH, American Cancer Society, and others. Awards include the NIH Director’s New Innovator Award and Lung Cancer Research Foundation grants. Her lab actively recruits postdoctoral researchers and offers rotation projects in CRISPR technology and cancer biology. Education: B.S. and M.S. in Biochemistry from Nanjing University; Ph.D. in Biochemistry from State University of New York, Stony Brook. Research Interests: Wen Xue’s lab employs CRISPR tools to accelerate cancer gene validation and therapeutic target identification. Projects include: CRISPR-based liver cancer gene correction and oncogene deletion studies. Investigating KRAS inhibition resistance via RNAi and CRISPR in lung cancer models. Characterizing miRNA networks using TCGA data to identify therapeutic miRNA candidates. Her work bridges functional genomics with precision medicine, emphasizing in vivo and in vitro platforms. Publications: Over 100 peer-reviewed articles, including high-impact studies on CRISPR applications in gene therapy and cancer modeling. Recent work explores prime editing, base editing, and viral/non-viral delivery systems for lung diseases. Grants & Awards: NIH grants (P01HL131471, DP2HL137167), American Cancer Society (RSG-16-093), and industry partnerships like the Cystic Fibrosis Foundation. Collaborations include projects on CFTR mutation repair and AAV vector development. Labs/Teams: Xue Lab focuses on cancer genetics and gene editing, with interdisciplinary collaborations in molecular medicine and bioengineering. Ongoing projects aim to translate CRISPR-based therapies into clinical applications.

Prashant Maliمشاهده پروفایل

استاد

• Genome Engineering
• RNA Editing
• Stem Cell Research
• +۴ مورد دیگر

Prashant Mali is a Professor in the Department of Bioengineering at the University of California, San Diego . His research bridges genome engineering, RNA biology, and biomedical applications, with a focus on CRISPR-Cas systems and ADAR-mediated RNA editing. Education : Ph.D. in Bioengineering Key Affiliations : UC San Diego, Altman Clinical and Translational Research Institute Dr. Mali's work centers on CRISPR-Cas9 technology , RNA editing , and human pluripotent stem cells . His lab develops tools for programmable gene regulation, synthetic lethal screens, and metabolic pathway analysis in disease contexts. Recent publications highlight innovations in circular RNA engineering , ADAR activity mapping , and metabolic reprogramming in cancer . His team employs multi-omics approaches and in vivo models to translate genome editing into clinical applications. Students and Collaborators Current Lab Members : Sami Nourreddine (Postdoc), Amir Dailamy (Graduate), Andrew Portell (Graduate), Michael Tong (Graduate) Alumni : Kyle Ford (PhD 2022), Nathan Palmer (PhD 2022), Udit Parekh (PhD 2021) Research Themes CRISPR Screens : Synthetic lethal interactions, oncogenic pathways, metabolic vulnerabilities RNA Editing : ADAR engineering, circular guide RNAs, clinical translation Tissue Engineering : Vascularized organoids, cardiac maturation, ex vivo models

Ravi Shuklaمشاهده پروفایل

استاد

• Nanobiotechnology
• Bioscience
• Medical Biotechnology
• +۶ مورد دیگر

Professor Ravi Shukla is a faculty member at RMIT University's School of Science, holding the title of Professor and Deputy Head of Department (Research). He specializes in Nanobiotechnology, with research spanning biomaterials, drug delivery systems, and medical diagnostics. His work integrates biosciences, materials science, and food technology to advance understanding of nanomaterial-biomolecular interactions. Academic History: Professor Shukla has held roles at RMIT since 2011, progressing from Research Fellow to his current professorship. He also serves as an Adjunct Professor at the University of Missouri and Theme Leader for Nanobiotechnology at RMIT’s Center for Advanced Materials and Industrial Chemistry. His teaching focuses on fostering student belonging and innovation in biotechnology education, including coordinating RMIT’s undergraduate Biotechnology program. Research Interests: His lab explores hybrid biomaterial synthesis, nano-enabled proteomics, and non-viral gene therapy using MOFs. Recent work emphasizes applications in diabetes biosensing, CRISPR/Cas9 delivery, and antimicrobial resistance mitigation through nanostrategies. Over 130+ publications and substantial research funding highlight his interdisciplinary impact. Professional Engagement: Editor roles in Frontiers in Bioengineering and Biotechnology , Co-Editor-in-Chief of Current Research in Nutrition and Food Science , and advisor to the Australasian Association of Ayurveda underscore his leadership. He actively mentors students in projects like nano-antimicrobial wound healing and aptamer-based hepatitis A detection. Key Achievements: Pioneered nucleic acid-encapsulated MOFs for cancer therapy and developed paper-based biosensors for rapid diagnostics. His work aligns with UN Sustainable Development Goals 2 (Zero Hunger) and 3 (Good Health).

Joanne Wangمشاهده پروفایل

استاد

• Blood-brain and blood-csf barriers
• Pharmacokinetics-Pharmacodynamics
• Pharmacology
• +۵ مورد دیگر

Joanne Wang is Professor of Pharmaceutics at the University of Washington School of Pharmacy and an Affiliate Investigator at the Fred Hutchinson Cancer Research Center. She holds additional appointments in multiple research centers including the Obstetric-fetal Pharmacology Research Unit (OPRU), Plein Center for Aging Faculty, and Pharmaceutics Faculty. Her educational background includes: PhD in Pharmaceutical Chemistry, University of California, San Francisco (UCSF) MS in Biochemistry, University of Illinois at Chicago BS in Biochemistry, Peking University Dr. Wang's research focuses on solute carrier (SLC) and ATP-binding cassette (ABC) transporters that shuttle drugs, nutrients, neurotransmitters, and hormones across cell membranes. Her work encompasses elucidating mechanisms and clinical impact of transporters in nutrient and drug disposition and their potential as drug targets. Ongoing projects include identification and functional characterization of transporters in human placenta, mechanisms of drug secretion into breastmilk using PBPK modeling, and investigation of transporters in the disposition of meta-iodobenzylguanidine for cancer therapy. Analysis of her recent publications reveals a strong emphasis on transporter-mediated drug disposition in special populations, particularly during pregnancy and lactation, and at the blood-brain barrier. Her work spans from basic transporter characterization to clinical applications, with increasing focus on translational aspects including PBPK modeling and clinical implications of transporter polymorphisms. Dr. Wang is actively involved in mentoring, as evidenced by her lab accepting students. Her research has been supported by significant grants including a UC2 grant from NICHD for placental transporter research. Her multidisciplinary approach integrates in vitro models, in vitro-in vivo extrapolation, and PBPK modeling to address critical questions in drug disposition. She is affiliated with several research centers including the Obstetric-fetal Pharmacology Research Unit (OPRU), Plein Center for Aging, and the Washington Entrepreneurial Research Evaluation and Commercialization Hub (WE-REACH), reflecting the breadth and impact of her work across multiple domains of pharmacology and therapeutics.

Yu-Chong Taiمشاهده پروفایل

استاد

• Medical Devices
• MEMS (Microelectromechanical Systems)
• Bio-MEMS
• +۷ مورد دیگر

Yu-Chong Tai is the Anna L. Rosen Professor of Electrical Engineering and Medical Engineering at the California Institute of Technology. He holds the Cherng Leadership Chair (2017–22) and has served as Executive Officer (2005–2008, 2013–22). His research focuses on applying MEMS/NEMS technologies to medical applications, including medical implants, microfluidics, and lab-on-a-chip systems. Tai leads the Caltech MEMS Laboratory, an 8,000-square-foot facility with clean-room and biological labs dedicated to biomedical device development. Education: B.S., National Taiwan University (1981); M.S., University of California (1986); Ph.D., 1989. Academic progression: Assistant Professor (1989–95) → Associate Professor (1995–2000) → Professor (2000–13) → Rosen Professor (2013–present). Research interests span medical devices, Bio-MEMS, microfluidics, drug delivery, and implantable systems like retinal prosthetics and spinal stimulators. His group collaborates with UCSF, USC, UCLA, and industry partners to advance neural implants and micro-scale medical technologies. Key awards: Member of the National Academy of Engineering, Elected to the National Academy of Inventors Notable projects include HPLC-on-a-chip, wireless drug delivery systems, and oxygen-permeable implant coatings. Tai teaches courses on medical device design and micro/nano technology, fostering interdisciplinary innovation.

• Immunology
• Gastroenterology
• Mucosal Immunology
• +۳ مورد دیگر

Mahima Swamy is a Principal Investigator and Wellcome Trust Sir Henry Dale Fellow at the MRC Protein Phosphorylation and Ubiquitylation Unit (PPU) at the University of Dundee. Her research focuses on understanding immune interactions at the intestinal epithelium, particularly the role of intraepithelial lymphocytes (IEL) in maintaining gut homeostasis and resisting infections. She leads a lab investigating IEL biology, including their regulation by PIM kinases and LRRK2 in inflammatory bowel diseases (IBD) and Crohn’s disease. Dr. Swamy earned her BSc in Biological Sciences from BITS Pilani and completed her PhD at the Max-Planck Institute in Freiburg, Germany. She held postdoctoral fellowships at CRUK London Research Institute and the University of Dundee before establishing her independent group in 2016. Her work combines proteomics, mouse models, and in vitro co-cultures to explore IEL signaling pathways and their dysregulation in diseases. Key research interests include: IEL-mediated protection against pathogens, metabolic adaptations of IEL to the gut environment, and the role of LRRK2 in intestinal immune function. Her lab collaborates with the Alessi lab to study LRRK2 inhibitors for IBD therapy. Education: BSc (BITS Pilani) → PhD (MPIIB, Germany) → Postdocs (CRUK, Dundee) Lab Members: Includes PhD students (Rebecca Pemberton, Srishti, Neema Skariah) and postdocs (Amanpreet Chawla, Purbasha Bhattacharya) Collaborations: Tayside Immunology Group, Society for Mucosal Immunology Scientific achievements include discoveries of PIM kinases in IEL function and LRRK2’s role in gut inflammation. Her group has pioneered tools like phospho-proteomic analyses and epithelial organoid:IEL co-cultures.

Marc Schneiderمشاهده پروفایل

استاد

• Colloidal drug delivery systems
• Nanoparticle and microparticle engineering
• Nanotechnology in pharmacy
• +۳ مورد دیگر

Prof. Dr. Marc Schneider holds a professorship in Biopharmaceutics and Pharmaceutical Technology at Saarland University's College of Pharmacy . His research focuses on colloidal drug delivery systems, particularly nanostructured and non-spherical particle engineering for overcoming biological barriers in pulmonary and transdermal applications. He leads an internationally recognized lab in Saarbrücken, collaborating with Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) and trinational institutions. Research Highlights: Development of inhalable nano/microparticle systems Surface modification of gelatin nanoparticles Characterization of mucus-penetrating particles 3D printing for microneedle fabrication Atomic Force Microscopy (AFM) for nanoparticle analysis Selected Scientific Awards: European Journal of Pharmaceutics and Biopharmaceutics Best Paper Award (2018) for mucus-penetrating nanoparticles Recognized in 'Ausgezeichnete Orte im Land der Ideen' competition (2018) for 'Nano-Mais' drug delivery system Collaborative Networks: Co-editor for Advanced Drug Delivery Reviews special issue on biological barriers Key participant in trinational Master's program in Biomedicine with Strasbourg, Mainz, and Luxembourg Active in Controlled Release Society (CRS) conferences and local chapters

• Biomaterials
• Tissue Engineering
• Regenerative Medicine
• +۵ مورد دیگر

João F. Mano is a Full Professor at the Department of Chemistry, University of Aveiro, and Director of the Doctoral Program on Biotechnology. He leads the COMPASS Research Group and serves as Vice-Director at CICECO - Aveiro Institute of Materials. His academic appointments include Invited Professor at University of Lorraine (France), Visiting Professor at KAIST (South Korea), and Adjunct Professor at Ajou University (South Korea). Education: PhD in Chemistry (1996, Technical University of Lisbon); D.Sc. in Tissue Engineering, Regenerative Medicine and Stem Cells (2012, University of Minho) Research Interests focus on Biomaterials for Regenerative Medicine , integrating Nanotechnology , Microtechnology , and Biofabrication . His group develops Bioinspired Materials using polymer chemistry, Decellularized Extracellular Matrix , and 3D Bioprinting to engineer Cell Microenvironments for therapeutic applications. Recent Publications highlight advancements in Human-Derived Hydrogels , Photopolymerizable Scaffolds , Magneto-Responsive Biomaterials , and Programmable Bioinks . Trends show emphasis on Organ-on-a-Chip integration, Smart Living Materials , and Green Bioprinting methodologies. Scientific Awards include: European Research Council Advanced Grants (2015, 2020) Fellow at IUPAC, European Academy of Sciences, and American Institute of Medical and Biological Engineering ERC Proof of Concept Grants Doctor Honoris Causa from University of Lorraine and Utrecht UNESCO Chair on Biomaterials George Winter Award (European Society for Biomaterials) Supervisions & Collaborations encompass 74+ MSc, 26+ PhD students, and 40+ postdocs. He co-founded METATISSUE and CELLULARIS Biomodels , and serves as Editor-in-Chief of Materials Today Bio .

Pia Vogelمشاهده پروفایل

استاد

• ATP Synthase
• Multidrug Resistance
• Ryanodine Receptor
• +۵ مورد دیگر

Pia Vogel is a Professor in the Department of Biological Sciences at Southern Methodist University (SMU), where she leads research on nucleotide-binding proteins using Electron Spin Resonance spectroscopy and molecular modeling. Her work focuses on elucidating structural mechanisms in ATP synthase, multidrug resistance transporters, and calcium channels with biomedical applications in cancer therapy and neurodegenerative diseases. Education: Ph.D., University of Kaiserlautern Dr. Vogel's research program investigates three interconnected domains: the rotary mechanics of FoF1-ATP synthase (particularly the external stalk subunit b-dimer), the structural basis of multidrug resistance in P-glycoprotein and MRPs, and ATP-regulated calcium release via ryanodine receptors. Her laboratory employs site-specific spin labeling, ESR spectroscopy, and computational modeling to resolve protein dynamics and interactions at molecular resolution, contributing to understanding energy transduction in ATP synthase and mechanisms of drug resistance. Analysis of her 15 most recent publications (2020-2025) reveals a dominant focus on developing and characterizing P-glycoprotein and BCRP inhibitors to overcome chemotherapy resistance in cancer. These studies integrate computational screening, ATPase assays, and cell-based models to evaluate inhibitor efficacy, with emerging applications in Alzheimer's research through amyloid-β transport studies. The work demonstrates consistent methodological synergy between biophysical characterization and therapeutic development. Dr. Vogel maintains an active research group supported by sustained funding, evidenced by continuous publication output and laboratory infrastructure. Her team employs multidisciplinary approaches spanning biophysics, biochemistry, and computational biology to address fundamental questions in membrane protein function. Her laboratory facilities in DLSB 221 include specialized Electron Spin Resonance instrumentation and dual Linux computing clusters for molecular dynamics simulations. The research environment supports collaborative projects extending her work into cancer therapeutics and neurodegenerative disease mechanisms through partnerships with clinical and computational researchers.

• Pharmaceutical Technology
• Drug Delivery
• Nanoparticles
• +۴ مورد دیگر

Jouni Hirvonen is a Professor in the Division of Pharmaceutical Chemistry and Technology at the University of Helsinki's Faculty of Pharmacy. He serves as Supervisor for doctoral programmes in both the Doctoral Programme in Drug Research and the Doctoral Programme in Materials Research and Nanosciences. With an extensive publication record spanning over three decades, Hirvonen has contributed 384 research outputs and participated in 3 major research projects. His research interests focus on pharmaceutical technology, particularly in drug delivery systems, nanoparticles, and drug dissolution and absorption. His work bridges pharmaceutical chemistry with cutting-edge nanotechnology applications, developing innovative delivery systems for therapeutic agents. His research spans from fundamental pharmaceutical sciences to translational applications in regenerative medicine, immunotherapy, and cardiovascular pharmacology. The analysis of his recent publications reveals a strong focus on advanced drug delivery platforms, particularly utilizing nanoparticles, lipid-based systems, and biomaterials for targeted delivery. His work increasingly integrates microfluidic technology for precise nanoparticle preparation, with applications spanning cancer immunotherapy, cardiovascular repair, tendon regeneration, and inflammatory disease treatment. The trend shows a growing emphasis on combination therapies, RNA delivery, and cell-mediated drug delivery approaches. Hirvonen has received several prestigious awards throughout his career: CRS/Eurand Grand Prize Award on Innovations in Oral Drug Delivery Technologies (2007) Suomen Valkoisen Ruusun Ritarikunnan I luokan ritarimerkki (2013) The Young Scientist in the University of Kuopio (1993) University of Helsinki Quality Teaching Unit, Faculty of Pharmacy (2005) Visiting Professor award (2015) With 25 instances of supervising doctoral theses and numerous academic activities including conference organization, committee memberships, and editorial work, Hirvonen has made significant contributions to academic mentorship and institutional development. His research has been supported by projects including Generation Green, 3i REGENERATION, and IVIVRe. His work appears to involve collaboration with multiple research teams focusing on drug delivery applications across various therapeutic areas.

Trond Vidar Hansenمشاهده پروفایل

استاد

• Organic Chemistry
• Biochemistry
• Pharmacology
• +۳ مورد دیگر

Trond Vidar Hansen is a Professor at the Department of Pharmacy, University of Oslo , and leads the LIPCHEM research group . He collaborates with institutions including the University of Bergen and Vestlandets Innovasjonsselskap through the VITADEL project, which recently received NOK 5,000,000 in verification support from the Research Council of Norway. His research focuses on the synthesis and biological evaluation of specialized pro-resolving lipid mediators derived from omega-3 fatty acids, with applications in inflammation resolution, neuroinflammation, and drug development. University : University of Oslo Department : Department of Pharmacy Research Group : LIPCHEM Collaborations : University of Bergen, Vestlandets Innovasjonsselskap Research Interests : H Hansen's work centers on the organic synthesis of bioactive lipid derivatives, particularly pro-resolving mediators from omega-3 polyunsaturated fatty acids. His team investigates their roles in inflammatory disease models , neuroinflammation , and PPAR receptor activation , aiming to develop therapeutic agents for conditions like chronic pain, diabetes, and neurodegenerative disorders. The research integrates stereoselective chemistry , biochemical profiling , and pharmacological evaluation to validate these mediators' clinical potential. Recent Awards : 2025: NOK 2,000,000 verification support from Research Council of Norway 2025: Co-leader of NOK 5,000,000 VITADEL project Publications : His articles (2015–2024) reveal a focus on stereoselective synthesis of resolvins, protectins, and maresins, with applications in anti-inflammatory and neuroprotective therapies . Key subfields include omega-3 metabolite profiling , PPAR agonist design , and biosynthetic pathway elucidation , often utilizing human cell models and mouse disease models . Collaborative projects emphasize commercialization of academic research and translational medicine .

Joanna Deaton Bertramمشاهده پروفایل

استادیار

• Medical Robotics
• Continuum Robotics
• Surgical Robotics
• +۴ مورد دیگر

Dr. Joanna Deaton Bertram is an Assistant Professor in the Thomas Lord Department of Mechanical Engineering and Materials Science at Duke University’s Pratt School of Engineering. She concurrently holds an Assistant Professor appointment in Surgery, underscoring her interdisciplinary commitment to advancing medical robotics. Dr. Bertram leads a research laboratory devoted to the design, modeling, and control of robotic systems for surgical and interventional applications, working closely with Duke’s clinical and engineering communities. Education Ph.D. in Robotics, Georgia Institute of Technology, 2024 M.S. in Mechanical Engineering, Georgia Institute of Technology, 2024 B.S. in Biomedical Engineering, Georgia Institute of Technology, 2018 Research Interests Dr. Bertram’s research program is centered on medical robotics , with particular emphasis on continuum robotics and image-guided interventions . Her work integrates novel mechanical design with advanced control algorithms and smart materials to create robotic systems capable of navigating complex anatomical pathways. A hallmark of her approach is the incorporation of real-time fiber-optic shape and force sensing (using Fiber Bragg Grating technology) to provide surgeons with unprecedented feedback during procedures. Application domains include steerable needles for brachytherapy , robotic guidewires for endovascular surgery , and pediatric neuroendoscopy . Publication Themes Across more than fifteen peer-reviewed articles, Dr. Bertram has systematically advanced the state of the art in surgical robotics , fiber-optic sensing , and robotic system modeling . Her 2024 tutorial on Nitinol and Tungsten tendon attachment techniques provides practical guidance for building highly articulated continuum robots, while her 2023 series on the COAST guidewire robot demonstrates model-based design and simultaneous shape/force sensing for large-deflection medical devices. Earlier work explored 3D-printed patient-specific robotic tools and carbon-nanotube flexible sensors, illustrating a trajectory from fundamental sensor research to full robotic system integration. Scientific Recognition & Collaboration Although no major external awards are explicitly listed, Dr. Bertram’s publications in top-tier venues such as IEEE Robotics and Automation Letters , IEEE Transactions on Medical Robotics and Bionics , and IEEE/ASME Transactions on Mechatronics attest to strong peer recognition. She actively invites motivated graduate students, post-docs, and research staff to join her lab, fostering an open and interdisciplinary environment. Advising & Grants Dr. Bertram’s lab is presently recruiting trainees at all levels. While specific funded grants are not enumerated, her dual departmental appointments and extensive publication record suggest active federal or foundation support. Prospective students and collaborators are encouraged to contact her directly at joanna.d.bertram@duke.edu . Laboratory & Teams Dr. Bertram directs a laboratory within Duke University’s Pratt School of Engineering that collaborates closely with clinicians in the School of Medicine. The group focuses on rapid prototyping of medical devices, in-vitro and ex-vivo validation, and translation of robotic technologies to the operating room.

Gianmarco Pintonمشاهده پروفایل

دانشیار

• Biomedical Imaging
• Ultrasound Imaging
• Traumatic Brain Injury
• +۴ مورد دیگر

Gianmarco Pinton is an Associate Professor in the Department of Biomedical Engineering at the University of North Carolina at Chapel Hill. His research focuses on nonlinear ultrasound and mechanical wave propagation, with applications to medical imaging and therapy. He specializes in traumatic brain injury, shear shock waves, and ultrasound therapy. Ph.D., M.S., and B.S.E. in Biomedical Engineering/Physics from Duke University His lab develops physics and simulation tools for nonlinear wave propagation, aiming to create advanced diagnostic ultrasound methods. Key areas include traumatic brain injury, transcranial imaging, and therapeutic ultrasound. His recent work explores super-resolution imaging, brain motor circuits, and Alzheimer's disease vascular mapping using ultrasound. Article trends highlight innovations in transcranial ultrasound, super-resolution techniques, lung imaging, and neuromodulation. His publications address image degradation, contrast agents, and shear wave dynamics in neurological contexts.

Yeonhwa Parkمشاهده پروفایل

استاد

• Functional Foods
• Obesity
• Environmental Contaminants
• +۳ مورد دیگر

Yeonhwa Park is a Professor and holder of the Francis Chair in the Department of Food Science at the University of Massachusetts Amherst. Her research focuses on functional foods, bioactive components, and environmental contaminants' effects on obesity and aging. She investigates food bioactives like conjugated linoleic acid (CLA) and environmental pollutants like PFAS to understand their roles in metabolic disorders and aging mechanisms. Her work spans multiple models, including C. elegans, zebrafish, and rodent studies, emphasizing translational applications for human health. Teaching responsibilities include courses such as 'Science of Food' (FS150), 'Biology of Food in Human Health' (FS270), and 'Bioactive Food Components' (FS750). Awards include Clarivate Highly Cited Researcher (2017–2018), Faculty Convocation Award (2015), and the Timothy Mounts Award (2015). Her research has been published in over 150 peer-reviewed articles, with recent emphasis on environmental contaminants' impact on obesity and type 2 diabetes, and the use of C. elegans for screening bioactives. Key findings include CLA's role in fat reduction, PFAS-induced metabolic disruption, and the application of alternative models (e.g., C. elegans) to reduce animal testing. Her lab integrates molecular biology, toxicology, and food science to address global health challenges like the obesity epidemic and environmental toxin exposure.

Kathryn A. Whiteheadمشاهده پروفایل

استاد

• Drug Delivery
• RNA Therapeutics
• Bionanotechnology
• +۴ مورد دیگر

Dr. Kathryn A. Whitehead is a Professor in the Department of Chemical Engineering and holds a courtesy appointment in the Department of Biomedical Engineering at Carnegie Mellon University. She joined the faculty in 2012 after completing postdoctoral training at MIT. Her research focuses on engineering drug delivery systems for RNA therapeutics, maternal-infant health, and overcoming biological barriers to enhance drug efficacy. Key areas include lipid nanoparticle (LNP) design for mRNA delivery, intestinal permeation enhancement, and leveraging maternal milk cells for therapeutic applications. Education: H.B.Ch.E., University of Delaware (2002); Ph.D., University of California, Santa Barbara (2007); Postdoctoral Fellow, MIT (2008–2012). Research Interests: Drug delivery systems, RNA interference, bionanotechnology, personalized medicine, and translational nanomedicine for diseases such as cancer and diabetes. Her lab develops novel LNPs for targeted delivery to tissues like the liver, brain, and pancreas. Awards and Recognition: AIMBE Fellow, DARPA Young Faculty Award (2016), CMBE Young Innovator Award (2016), MIT Technology Review Innovator Under 35 (2014), and NIH Director’s New Innovator Award. Her work has been cited over 9,000 times, with patents in RNA delivery and permeation enhancers. Lab Members: Active researchers include Ph.D. students, postdocs, and undergraduates working on projects such as LNP formulation, maternal milk cell biology, and siRNA therapies. Notable alumni have advanced to roles at Moderna Therapeutics, Verve Therapeutics, and academic institutions. Grants and Funding: Supported by NIH, DARPA, and industry partnerships. Current projects include NIH grants on pregnancy-safe mRNA delivery and DARPA funding for maternal-infant therapeutics.